nivolumab,cabozantinib
bms
['nivo', 'rcc,(-irccs),(-srcc),(-urcc)']
extended f/u of cabonivo: ph2 cabo+nivo in non-ccrcc pts (n=40) at 34 mo orr: 48%; median dor: 17 mo pfs: median 13 months; 1-yr: 51%, 2-yr: 23% os: 28 mo; 18-mo: 70%, 36 mo: 44$ gr3+ aes: 55% (ast/alt : 18-23%; htn: 5-13%, pain: 4-10%) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧